BRII-B News

Tengsheng Pharmaceutical-B (02137.HK) 2022 Review Report: Anti-infection, self-research with rich layout in the CNS field, cooperative two-wheel drive

興業證券Mar 27, 2023 07:57

Tenshengbo Pharmaceutical-B (02137.HK): Entering the commercialization stage and introducing further strengthening the HBV pipeline

興業證券Aug 28, 2022 00:00

Tenshengbo Pharmaceutical (2137.HK): A rising star in hepatitis B treatment focuses on international BIOTECH in the fields of infectious diseases and CNS

光大證券Jul 20, 2022 19:16

Tenshengbo Drug-B (02137.HK): COVID-19 Neutralizing Antibody Approved, Hepatitis B SIRNA Drug Shows Potential

中金公司Mar 23, 2022 00:00

Tenshengbo Pharmaceutical-B (02137.HK): China approves the first COVID-19 neutralizing antibody drug with independent intellectual property

國金證券Dec 8, 2021 00:00

Tenshengbo Drug-B (02137.HK): Hepatitis B siRNA therapy data positive

中金公司Nov 18, 2021 00:00

Tenshengbo Pharmaceutical (02137.HK): A rising star on the public health circuit with innovative treatments focusing on infectious diseases and CNS

興業證券Jul 9, 2021 00:00

IPO Preview: Tenshengbo Pharmaceutical-B (2137.HK)

光大新鴻基Jun 30, 2021 00:00

IPO News: Tengshengbo Pharmaceutical Biotechnology Co., Ltd. - B (2137.HK)

致富證券Jun 30, 2021 00:00